Stress makes us crave foods we don't need. And it's often sugary, packaged foods we tend to grab in those tense times. But ...

Commercial weight loss programs have long been a popular option for those looking to shed a few pounds or manage their weight, but recently, they’ve evolved dramatically—parti ...

While these medications offer unprecedented health benefits, they come with challenges like cost, non-adherence and lack of ...

Injectables for type 2 diabetes and weight loss could soon be a thing of the past. Eli Lilly announced Thursday the successful completion of a phase 3 trial of Orforglipron – the first small ...

Orforglibron, a pill form of GLP-1 weight loss injections like Ozempic and Mounjaro, is undergoing clinical trials. Drugmaker Eli Lilly said the first trial showed similar weight loss and diabetes ...

The trial results showed significant A1C reduction and weight loss, which are seen as competitive to Novo’s offerings. The ACHIEVE-1 trial results revealed an average A1C reduction of 1.3-1.6% across ...

The experimental pill resulted in weight loss of nearly 8% at the highest dose, and lowered blood sugar in patients with type 2 diabetes. Today's pop helped Eli Lilly stock fully recover from its ...

The trial results showed significant A1C reduction and weight loss, which are seen as competitive to Novo’s offerings. The ACHIEVE-1 trial results revealed an average A1C reduction of 1.3-1.6% ...

But this one, for Lilly’s first diabetes and weight-loss pill based on the GLP-1 hormone ... called orforglipron, was a success. For the diabetes patients in the study, taking the drug daily lowered ...